DDR1 and non-small cell lung carcinoma: To address this gap, we aim to investigate DDR1 degraders and identify DDR1-associated DUBs, offering potential new therapeutic strategies for the treatment of non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).